Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock - par value $0.001 per share
-
Shares outstanding
-
48,247,400
-
Total 13F shares
-
48,364,380
-
Share change
-
+4,657,492
-
Total reported value
-
$2,003,585,519
-
Put/Call ratio
-
0%
-
Price per share
-
$41.43
-
Number of holders
-
141
-
Value change
-
+$199,192,055
-
Number of buys
-
97
-
Number of sells
-
27
Institutional Holders of Maze Therapeutics, Inc. - Common Stock - par value $0.001 per share (MAZE) as of Q4 2025
As of 31 Dec 2025,
Maze Therapeutics, Inc. - Common Stock - par value $0.001 per share (MAZE) was held by
141 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,364,380 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., TRV GP IV, LLC, Deep Track Capital, LP, ARCH Venture Management, LLC, JANUS HENDERSON GROUP PLC, BlackRock, Inc., a16z Capital Management, L.L.C., VANGUARD GROUP INC, VR ADVISER, LLC, and Alphabet Inc..
This page lists
141
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.